Guardant Health Lands $100,000,000 Series D Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=014db92e-45f6-423f-9d9f-cc53650f67f0 - Date
1/7/2016 - Company Name
Guardant Health - Mailing Address
505 Penobscot Dr. Redwood City, CA 94063 USA - Company Description
Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options. - Website
http://www.guardanthealth.com - Transaction Type
Venture Equity - Transaction Amount
$100,000,000 - Transaction Round
Series D - Proceeds Purposes
The funding will help Guardant Health build on its leading technological and commercial positions to further expand the adoption of Guardant360, the world’s first comprehensive, non-invasive genomic sequencing test for cancer. The investment will go toward Guardant Health’s Digital Sequencing platform to power additional breakthrough products geared toward addressing the full spectrum of the cancer-care continuum. - M&A Terms
- Venture Investor
OrbiMed - Venture Investor
Khosla Ventures - Venture Investor
Sequoia Capital - Venture Investor
Lightspeed Venture Partners - Venture Investor
Pejman Mar Ventures - Venture Investor
Formation 8 - Venture Investor
Heritage Group - Venture Investor
Felicis Ventures
